Fund moves
6.9%Stake
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
SNTI · NASDAQ · Biological Products, (No Diagnostic Substances)
Senti Biosciences Holdings (SNTI) · oqro.io/stocks/SNTI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$1.77−1.02 (−36.56%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Senti Biosciences Holdings is on record in SEC filings since 2006.
Since 2025, Senti Biosciences Holdings insiders reported 0 open-market purchases and 4 sales on Forms 4 and 5.
No open-market sale by an insider of Senti Biosciences Holdings (SNTI) was filed with the SEC in the last 90 days.
No trade in Senti Biosciences Holdings (SNTI) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−97.0% (−$57.96) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $59.73 on Nov 20, 2025 to $1.77 on Nov 20, 2026 (−97.0%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biological Products, (No Diagnostic Substances) company based in South San Francisco, Ca.
Last 12 months
−95.2%
Market value
$86.9M
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 1.12M shares sold short (3.6% of shares outstanding), +160.9% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$22K
Year ended Dec 31, 2025
Net income, fiscal 2025
−$61.4M
A loss for the year
Shares outstanding
31.1M
As of Jul 31, 2026
Reverse split 1-for-33 took effect Nov 19, 2026. Calendar
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Fund moves
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$19K
Year earlier: $0
Free cash flow, last 12 months
−$6.73M
This quarter −$6.73M, a year earlier −$9.45M
Net debt
—
Debt —, cash $5.55M, at Sep 30, 2026
Net income, last 12 months
−$43M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Jul 15, 2026.
Revenue and earnings history, 5 fiscal yearsEarnings dates and the stock's moves
Notice of delisting or failure to meet listing rules
8-K on sec.govNotice of delisting or failure to meet listing rules
8-K12B on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Insiders of Senti Biosciences Holdings reported 0 open-market purchases and 4 sales since 2025; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $24K4×4 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Against the S&P 500 over the year
Since Nov 18, 2025, SNTI is down 95.1% and the index fund is up 8.5%: 104 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much SNTI moves
Beta 2.4 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
New Enterprise Associates 15, L.P.
13D · may seek influence · Amended · 8.78M shares · filed Nov 18, 2026
Bayer HealthCare LLC
13D · may seek influence · Amended · 6.14M shares · filed Nov 18, 2026
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Deals
Things to keep in mind
Records
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 8,000 words.
We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments.
And 23 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: about 5.8 million shares a week traded away from the exchanges over the latest 4 published weeks, 343 thousand of them on ATS. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: BOATS (71.2%), IBKR ATS (8.5%), LEVEL ATS (2.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others.
Latest annual report filed Mar 27, 2026, compared with the one filed Mar 20, 2025. Read the filing
From time to time we may become involved in legal proceedings to claims arising in the ordinary course of our business. We are not currently a party to any such material legal proceedings.
Source: SEC EDGAR, Form 10-K filed Mar 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.